Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics (NASDAQ: ACRS) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:00 p.m. ET. The presentation will provide a company overview, which can be accessed via a live audio webcast on Aclaris’ website, with an archived version available for 30 days. Aclaris is dedicated to treating immuno-inflammatory diseases, featuring a diverse portfolio that includes a late-stage drug candidate supported by a strong R&D initiative.
Aclaris Therapeutics reported financial results for Q1 2020, highlighting a net loss of $15.6 million, down from $37.6 million in Q1 2019.
Cash and equivalents rose to $79 million, with $11 million borrowed from Silicon Valley Bank to extend its cash runway into Q1 2022. The company resumed enrollment in its Phase 2a trial for ATI-450 amidst COVID-19 disruptions. R&D expenses decreased to $9.4 million, a drop of $10.2 million from the previous year, alongside a $1.8 million non-cash charge impacting financial results. Aclaris continues to seek partners for various product developments.